The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 14, 2021

Filed:

Jul. 02, 2020
Applicant:

Pfizer Inc., New York, NY (US);

Inventors:

Andrew Fensome, Harvard, MA (US);

Ariamala Gopalsamy, Lexington, MA (US);

Brian S. Gerstenberger, Cambridge, MA (US);

Ivan Viktorovich Efremov, Chestnut Hill, MA (US);

Zhao-Kui Wan, Lexington, MA (US);

Betsy Pierce, East Lyme, CT (US);

Jean-Baptiste Telliez, Lexington, MA (US);

John I. Trujillo, Ledyard, CT (US);

Liying Zhang, Malden, MA (US);

Li Xing, Lexington, MA (US);

Eddine Saiah, Brookline, MA (US);

Assignee:

Pfizer Inc., New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61K 31/55 (2006.01); A61K 45/06 (2006.01); C07D 401/14 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 487/08 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/55 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01); C07D 401/14 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 487/08 (2013.01); C07D 519/00 (2013.01);
Abstract

A compound compound having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C-Calkyl, C-Calkoxy, C-Ccycloalkyl, aryl, heteroaryl, aryl(C-Calkyl), CN, amino, alkylamino, dialkylamino, CF, or hydroxyl; A is selected from the group consisting of a bond, C═O, —SO—, —(C═O)NR—, and —(CRR)—, where Ris H or C-Calkyl, and Rand Rare independently hydrogen, deuterium, C-Calkyl, C-Ccycloalkyl, aryl, aryl(C-Calkyl), heteroaryl, (C-Calkyl)heteroaryl, etc.; A' is selected from the group consisting of a bond, C═O, —SO—, —(C═O)NR′, —NR′(C═O)—, and —(CR′R′)—, where R′ is H or C-Calkyl, and R′ and R′ are independently hydrogen, deuterium, C-Calkyl, C-Ccycloalkyl, aryl, aryl(C-Calkyl), heteroaryl, (C-Calkyl)heteroaryl, heteroaryl(C-Calkyl), and heterocyclic(C-Calkyl); Z is —(CH)— or a bond, where one or more methylene units are optionally substituted by one or more C-Calkyl, CN, OH, methoxy, or halo, and where said alkyl may be substituted by one or more fluorine atoms; Rand R′ are independently selected from the group consisting of hydrogen, deuterium, C-Calkyl, C-Ccycloalkyl, aryl, heteroaryl, aryl(C-Calkyl), CN, etc., wherein said alkyl, aryl, cycloalkyl, heterocyclic, or heteroaryl is further optionally substituted with one or more substituents selected from the group consisting of C-Calkyl, halo, CN, C-Calkylamino, C-Ccycloalkyl, etc.; Ris selected from the group consisting of hydrogen, deuterium, C-Calkyl, C-Ccycloalkyl, halo, and cyano, where said alkyl may be substituted by one or more fluorine atoms; Ris selected from the group consisting of hydrogen, deuterium, and amino; Ris monocyclic or bicyclic aryl or monocyclic or bicyclic heteroaryl wherein said aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of C-Calkyl, heterocycloalkyl, halo, C-Ccycloalkyl, etc., where said alkyl, cycloalkyl, alkoxy, or heterocycloalkyl may be substituted by one or more C-Calkyl, halo, CN, OH, alkoxy, amino, —COH, —(CO)NH, —(CO)NH(C-Calkyl), or —(CO)N(C-Calkyl), and where said alkyl may be further substituted by one or more fluorine atoms; Ris independently selected from the group consisting of hydrogen, C-Calkyl, C-Calkoxy, and hydroxyl; h is 1, 2 or 3; j and k are independently 0, 1, 2, or 3; m and n are independently 0, 1 or 2; and, q is 0, 1 or 2. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations with other therapeutic agents.


Find Patent Forward Citations

Loading…